Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    No Appointments, No Nurses, No Private Insurance Needed

    22. Oktober 2025

    AHA urges tariff exceptions for certain PPE, medical devices

    21. Oktober 2025

    Popular Protein Powders, Shakes Test Positive for Lead. Are They Safe?

    21. Oktober 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»News»MDMA warns Section 232 tariffs could hurt US medtech manufacturing
    News

    MDMA warns Section 232 tariffs could hurt US medtech manufacturing

    HealthradarBy Healthradar21. Oktober 2025Keine Kommentare3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    MDMA warns Section 232 tariffs could hurt US medtech manufacturing
    Share
    Facebook Twitter LinkedIn Pinterest Email


    This audio is auto-generated. Please let us know if you have feedback.

    Dive Brief:

    • The Medical Device Manufacturers Association has warned that applying more tariffs to medical technologies will undermine efforts to reshore manufacturing and strengthen domestic production.
    • MDMA, which publicized its position Monday, shared the feedback in response to a Section 232 investigation that could lead the U.S. to apply targeted tariffs to imports of medical equipment.
    • The trade group said the tariffs could incentivize companies to stop serving other countries from U.S. facilities, disadvantage American businesses in global markets and raise device prices.

    Dive Insight:

    The Trump administration is running the Section 232 investigation to understand the potential national security risks of the U.S.’s reliance on imports of certain medical consumables and equipment. As part of the process, the administration has sought public feedback. AdvaMed recently submitted its response, arguing that tariffs could drive supply disruptions and cost increases.

    MDMA, another medtech trade group, made some similar points to AdvaMed in its response. Mark Leahey, president and CEO of MDMA, said in a statement that tariffs would “needlessly disrupt a globally integrated industry that already meets domestic demand, complies with rigorous regulatory standards and supports American innovation and jobs.”

    As well as arguing against Section 232 tariffs, MDMA shared advice on what the administration should do if it decides sector-specific levies are needed. Many of MDMA’s recommendations overlap with points that AdvaMed made to the administration. 

    Both trade groups support the U.S. reaching reciprocal tariff relief agreements with preferred trading partners and maintaining the pact with Canada and Mexico. Other points of agreement include a call for a phased implementation of any tariffs and the continuation of duty drawback to keep U.S. exports competitive.

    Other recommendations are unique to MDMA. The trade group put more emphasis on strengthening intellectual property than AdvaMed, calling for the government to advance targeted trade enforcement efforts in response to “persistent threats from markets like China.” MDMA also pitched stockpiling as a way for the U.S. to achieve its goals.

    “An alternative means to achieve U.S. medical supply chain resiliency is leveraging public-private partnerships. There’s an opportunity to stockpile medical supplies to enhance U.S. national security,” MDMA said. “These systems exist already, including the Strategic National Stockpile, and through other private means.”

    The Section 232 comment period ended Oct. 17. Amid a government shutdown, Regulations.gov is yet to publish any comments on the consultation docket. Organizations including the American Hospital Association, Business Roundtable, the U.S. Chamber of Commerce, the Health Industry Distributors Association and the National Association of Manufacturers have shared comments via other channels.

    All of the organizations raised concerns about Section 232 tariffs, joining AdvaMed and MDMA in noting the potential for further levies to cause disruption while failing to boost supply resiliency and domestic production.



    Source link

    hurt Manufacturing MDMA medtech Section tariffs warns
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleXiaomi Smart Band 10 review: few upgrades over the best cheap fitness tracker around
    Next Article Popular Protein Powders, Shakes Test Positive for Lead. Are They Safe?
    ekass777x
    Healthradar
    • Website

    Related Posts

    News

    AHA urges tariff exceptions for certain PPE, medical devices

    21. Oktober 2025
    News

    Hologic to go private for up to $18.3B

    21. Oktober 2025
    News

    HLTH 2025 Day 1 Summary & Insights Coverage

    21. Oktober 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202568 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202524 Views

    Linea Expands AI-Powered Heart Failure Care Solution

    6. August 202519 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20259 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202568 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202524 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.